The British Pharmacopoeia 2018 now available
pharmafile | July 24, 2017 | Feature | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | British Pharmacopoeia, biotech, drugs, healthcare, pharma, pharmaceutical
The British Pharmacopoeia (BP) 2018 is now published and available for purchase. An essential text for anyone working to develop medicines for UK and international use, the BP 2018 comprises of more than 250 new or amended monographs, including those from the European Pharmacopeia. Updated annually, the BP includes approximately 4,000 monographs which are legally enforced by the Human Medicines Regulations 2012.
“We’re proud that the BP is used widely in pharmaceutical development, manufacture and testing of medicines, in over 100 countries and is recognised internationally – it demonstrates the BP’s invaluable role in protecting public health in the UK and globally”, said James Pound, Group Manager British Pharmacopoeia & Laboratory Service. “We’re pleased to have been able to launch the 2018 edition earlier this year, providing users with additional time to comply, while still delivering a great-value and flexible package providing printed copies, online access and downloadable offline use.”
New for the BP 2018
The British Pharmacopoeia (BP) 2018 supersedes the BP 2017 and becomes legally effective on 1 January 2018. This edition incorporates new BP and European Pharmacopoeia monographs and a significant number of revised monographs.
- 35 new BP monographs, 39 new Ph. Eur. monographs
- 185 amended BP monographs
- Four new monographs for unlicensed formulations
- Four new monographs for herbal medicines
- All European Pharmacopoeia monographs integrated (9th Edition as amended by Supplements 9.1 to 9.2)
- Three in-year website and offline download updates to harmonise with the European Pharmacopoeia Supplements 9.3, 9.4 and 9.5
Various formats and package options are available.
Get ready for the new standards, place your order today.
Related Content
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
